Two-component Radiology-guided Autonomous Cascade Engine (TRACE)

NCT07651644 · tracked via the Priya Life Science China tracker

Sponsor

Liaoning Cancer Hospital & Institute

Phase

Not applicable

Started

2026-06-18

Last updated

2026-06-16

Condition(s) studied

Gastric Cancer (Diagnosis)

Investigational drug(s) / intervention(s)

Utilizing the TRACE model to assist radiologists in T-stagingwashout periodUtilizing the TRACE model to assist radiologists in T-staging

Utilizing the TRACE model to assist radiologists in T-staging: AI-assisted reading: Radiologists interpret preoperative contrast-enhanced CT images for gastric cancer T staging with the support of the TRACE artificial intelligence decision system. The AI system provides a suggested T stage and relevant imaging features. The radiologist makes the final staging decision after reviewing the AI output. This intervention is used only during the AI-assisted reading session.

washout period: Participants are required to observe a washout period of at least 30 days between consecutive interventions/assessments.

Study summary

This study employed a prospective, randomised crossover trial design to evaluate the clinical utility of the TRACE artificial intelligence system for gastric cancer T-staging. A total of 54 radiologists from tertiary and non-tertiary hospitals, including both senior and junior practitioners, were enrolled. The study aimed to investigate whether AI-assisted diagnosis could improve the diagnostic accuracy of gastric cancer T-staging compared with independent interpretation by radiologists.

All participants were required to interpret 60 contrast-enhanced CT cases sequentially, completing two readings for each case: one without AI assistance and one with AI assistance; The order of the two readings was randomised, and a one-month washout period was observed between readings to eliminate memory bias. All cases were pathologically confirmed gastric cancer cases (stages T1-T4b), and the study simultaneously recorded the physicians' T-staging diagnostic results and the time taken per case. The 60 cases per radiologist were randomly selected from a pool of 1,000 histologically confirmed gastric cancer cases, stratified by pathological T stage T1-T4b. The reference standard was postoperative pathological T stage. The primary outcome was the change in T-staging accuracy between AI-assisted reading and standard (unaided) reading.The term "prospective" in this study refers to the prospective execution of radiologist enrollment, randomization, reading procedures, and data collection.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria (Imaging Data) 1. Contrast-enhanced CT (CE-CT) images of gastric cancer patients from the Liaoning Cancer Hospital; 2. Patients with a definitive postoperative pathological diagnosis of gastric cancer and a clear T-stage classification (T1-T4, including T4a and T4b); 3. Imaging data must be complete and of sufficient quality to meet diagnostic and analytical requirements, with no significant artefacts or missing key data; 4. Complete clinical and pathological information must be available to establish a diagnostic gold standard for comparison. Physician Inclusion Criteria (Image Readers) 1. Radiologists holding a valid medical licence; 2. From the radiology department of a Grade A tertiary hospital or a non-Grade A tertiary hospital; 3. Classified as senior or junior physicians based on clinical experience; 4. Voluntarily participating in this study and completing both the non-AI-assisted and AI-assisted image interpretation tasks. Case Exclusion Criteria 1. Severe missing imaging data or quality failing to meet analysis requirements (e.g., severe motion artefacts); 2. Lack of clear postoperative pathological T-staging results; 3. Cases not involving gastric cancer or with incomplete pathological information; 4. Cases of duplicate enrolment or inconsistent data recording. Physician Exclusion Criteria 1. Those unable to complete all image review tasks or demonstrating severe non-compliance; 2. Those who withdraw during the study period and are unable to provide complete data for both phases of image review; 3. Those who fail to complete the AI-assisted and non-AI-assisted interpretation processes as specified. Withdrawal Criteria 1. Physicians who voluntarily withdraw from the study for personal reasons (e.g., time, health or work commitments); 2. Physicians who fail to complete the required image review tasks or have data missing in excess of the specified threshold; 3. Cases where critical data errors are identified during subsequent verification or where pathological results cannot be traced; Data found during the study to be non-compliant with ethical or quality control requirements must be excluded.

Primary outcome measure(s)

Accuracy — Within 40 days after the first radiologist initiates image reading.
Accuracy of radiologists' interpretation of T staging

Trial sites (1)

Facility	City	Region	Status
Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute)	Shenyang	Liaoning	Recruiting

More Liaoning Cancer Hospital & Institute trials in China

Optimal Application Timing of ADC Drugs for Advanced Breast Cancer Recruiting

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma Starting soon

Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery Recruiting

Other trials for the same condition

Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD Starting soon

TAIC FOLFOX for Locally Advanced G/GEJA Recruiting

DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective) Recruiting

High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease Starting soon

A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07651644 on ClinicalTrials.gov ↗ ← All trials in China